Fig. 1From: The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world settingParticipant flow diagram. a: Number of participants that had acceptable baseline and at least one follow up LCI2.5 measurement. b: Two participants left the study to enrol in industry led clinical trials. c: CT chest performed on a subgroup of participantsBack to article page